LABELS · 64b7451d-b06d-486b-9b34-a55001711063

Adalimumab-adbm

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-11-12
Captured: 2026-09-09T23:37:51.659493+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS AND MALIGNANCY WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning . SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue Adalimumab-adbm if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-adbm. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products. SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-adbm, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-adbm if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-adbm use and during therapy. Initiate treatment for latent TB prior to Adalimumab-adbm use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with Adalimumab-adbm prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-adbm, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2) ]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] .

Indications and usage: exact source text

1 INDICATIONS AND USAGE Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-adbm can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-adbm can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-adbm is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease Adalimumab-adbm is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-adbm is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ]. 1.7 Plaque Psoriasis Adalimumab-adbm is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-adbm should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-adbm is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-adbm is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

Full extracted label fields

application numbers

BLA761058

boxed warning exact

WARNING: SERIOUS INFECTIONS AND MALIGNANCY WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning . SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue Adalimumab-adbm if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-adbm. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products. SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-adbm, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-adbm if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-adbm use and during therapy. Initiate treatment for latent TB prior to Adalimumab-adbm use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with Adalimumab-adbm prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-adbm, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2) ]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] .

brand names

Adalimumab-adbm

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9986706-9c75-4335-a54f-09d7716dbcef

generic names

ADALIMUMAB-ADBM

64b7451d-b06d-486b-9b34-a55001711063

indications and usage exact

1 INDICATIONS AND USAGE Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-adbm can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-adbm can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-adbm is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease Adalimumab-adbm is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-adbm is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ]. 1.7 Plaque Psoriasis Adalimumab-adbm is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-adbm should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-adbm is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-adbm is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

indications and usage tables exact

is original packager

true

manufacturer names

QUALLENT PHARMACEUTICALS HEALTH LLC

matched search terms

tumor

package ndcs

82009-148-22
82009-149-11
82009-144-22
82009-145-11
82009-146-22
82009-147-11
82009-150-22
82009-151-11

product ndcs

82009-144
82009-148
82009-146
82009-150

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage, Hidradenitis Suppurativa ( 1.8 ) 10/2025 Uveitis ( 1.9 ) 10/2025 Dosage and Administration, Juvenile Idiopathic Arthritis or Pediatric Uveitis ( 2.3 ) 10/2025 Hidradenitis Suppurativa ( 2.7 ) 10/2025 Warnings and Precautions, Autoimmunity ( 5.9 ) 10/2025

record type

complete_spl_indications_section_candidate

routes

rxcuis

797544
2640883
2640895
2680743
2680748

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00400.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 515
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 0

current approval status

not_reconciled

duplicate text group

dup-00be609cef1c9d7f31af

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-2568679af846e823e68e

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 90
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 40

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
kind
age
polarity
not_inferred
span
end
257
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
243

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 315
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 666
end exclusive: true
exact text: ymptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and sy
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 116

current approval status

not_reconciled

duplicate text group

dup-635663326992ce32c86f

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-c962f6ef797cc6764095

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
455
end exclusive
true
exact text
2 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
441

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 466
end exclusive: true
exact text: ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 316

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 836
end exclusive: true
exact text: rately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 267

current approval status

not_reconciled

duplicate text group

dup-0ef8930dce0a0424647f

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-645ff54def56d078bde8

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 90
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 40

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
kind
age
polarity
not_inferred
span
end
602
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
588

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 636
end exclusive: true
exact text: ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 467

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 927
end exclusive: true
exact text: nts 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 437

current approval status

not_reconciled

duplicate text group

dup-2cdce931a467839bae83

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-f124183349a168c03145

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 90
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 40

qualifier mentions

context exact
( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
kind
age
polarity
not_inferred
span
end
690
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
676

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 727
end exclusive: true
exact text: ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 637

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1053
end exclusive: true
exact text: on of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or we
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 528

current approval status

not_reconciled

duplicate text group

dup-55a7df7d33f412e223a8

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-b5b08dc47cc89ef724f9

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 90
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 40

qualifier mentions

context exact
eatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
804
end exclusive
true
exact text
adults
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
798
context exact
moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
827
end exclusive
true
exact text
pediatric patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
809
context exact
ely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
842
end exclusive
true
exact text
6 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
828

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 853
end exclusive: true
exact text: ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 728

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1142
end exclusive: true
exact text: signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chroni
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 654

current approval status

not_reconciled

duplicate text group

dup-5b11a0c324c46df7cdd3

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-eb7efd5e7fe86f542f2f

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
ment of moderately to severely active ulcerative colitis in adult patients.
kind
age
polarity
not_inferred
span
end
941
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
927

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 942
end exclusive: true
exact text: ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 854

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · limitation of use

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1283
end exclusive: true
exact text: nt of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 743

current approval status

not_reconciled

duplicate text group

dup-bc9be91c4ecbd0125f04

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-f998f7b087cd1099760a

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1083
end exclusive: true
exact text: ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 943

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1483
end exclusive: true
exact text: y to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pedia
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 884

current approval status

not_reconciled

duplicate text group

dup-5dfcc63d03b22cef49aa

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-2d61fafe1679fda20843

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
Treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
kind
age
polarity
not_inferred
span
end
1111
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1097

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1283
end exclusive: true
exact text: Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1084

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1587
end exclusive: true
exact text: Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-adbm is indicated fo
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1084

current approval status

not_reconciled

duplicate text group

dup-b32449f860b3e3cfa390

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-b8aa2a54fe66da4a87f9

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
kind
age
polarity
not_inferred
span
end
1376
end exclusive
true
exact text
12 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1361

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1387
end exclusive: true
exact text: ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1284

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1722
end exclusive: true
exact text: emic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physica
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1188

current approval status

not_reconciled

duplicate text group

dup-dcf84c8d3eae5ebe374e

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-80ba61792d0b4517f41e

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1473
end exclusive
true
exact text
adults
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1467
context exact
tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1496
end exclusive
true
exact text
pediatric patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1478
context exact
posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1511
end exclusive
true
exact text
2 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1497

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1522
end exclusive: true
exact text: ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1388

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1730
end exclusive: true
exact text: hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical functi
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1323

current approval status

not_reconciled

duplicate text group

dup-da4c025b6a1e26431c05

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-dd6f4987725423aea06f

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1530
end exclusive: true
exact text: ( 1.9 )
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1523

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2007
end exclusive: true
exact text: nitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-adbm is indic
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1331

current approval status

not_reconciled

duplicate text group

dup-ea03d66124fe105da58a

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-12ce37a3238c8f50d653

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 1584
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1572

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
kind
age
polarity
not_inferred
span
end
1750
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1736

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1807
end exclusive: true
exact text: 1.1 Rheumatoid Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1531

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 13 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2148
end exclusive: true
exact text: symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1608

current approval status

not_reconciled

duplicate text group

dup-9311c426ed4f44268fdf

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-a775c7bb19c8e6ae8d11

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
kind
biomarker
polarity
not_inferred
span
end
1908
end exclusive
true
exact text
methotrexate or other non-biologic disease-
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1865
context exact
Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
kind
regimen
polarity
not_inferred
span
end
1947
end exclusive
true
exact text
in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
1845

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1948
end exclusive: true
exact text: Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1808

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2358
end exclusive: true
exact text: s with moderately to severely active rheumatoid arthritis. Adalimumab-adbm can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-adbm can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inhibiting the progression of structural d
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1749

current approval status

not_reconciled

duplicate text group

dup-d47503956358b66b117f

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-1947d9f9e0c15e239618

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 2011
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1999

qualifier mentions

context exact
ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
2147
end exclusive
true
exact text
2 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2133

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2158
end exclusive: true
exact text: 1.2 Juvenile Idiopathic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1949

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 15 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2429
end exclusive: true
exact text: le Idiopathic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-adbm can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active ps
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 1959

current approval status

not_reconciled

duplicate text group

dup-26a037099e7530f7b5c9

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-95cb977e3525c27699a2

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
Adalimumab-adbm can be used alone or in combination with methotrexate.
kind
biomarker
polarity
not_inferred
span
end
2228
end exclusive
true
exact text
methotrexate
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2216
context exact
Adalimumab-adbm can be used alone or in combination with methotrexate.
kind
regimen
polarity
not_inferred
span
end
2228
end exclusive
true
exact text
in combination with methotrexate
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2196

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2229
end exclusive: true
exact text: Adalimumab-adbm can be used alone or in combination with methotrexate.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2159

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2647
end exclusive: true
exact text: and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-adbm can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-adbm can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-adbm is indicated for reducing signs and symptoms in adult patients with active ank
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2030

current approval status

not_reconciled

duplicate text group

dup-835d5d011d0f59f3cf15

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-701b7da203b6d9194632

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 2282
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2270

qualifier mentions

context exact
on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
kind
age
polarity
not_inferred
span
end
2414
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2400

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2447
end exclusive: true
exact text: 1.3 Psoriatic Arthritis Adalimumab-adbm is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2230

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 17 · unclassified context

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2725
end exclusive: true
exact text: ritis Adalimumab-adbm is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-adbm can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-adbm is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease Adalimumab-adbm is indicated for the
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2248

current approval status

not_reconciled

duplicate text group

dup-a13573be7466046b969f

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-2ce8669f0dd11d3b4345

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

context exact
Adalimumab-adbm can be used alone or in combination with non-biologic DMARDs.
kind
regimen
polarity
not_inferred
span
end
2524
end exclusive
true
exact text
in combination with non-biologic DMARDs
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2485

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2525
end exclusive: true
exact text: Adalimumab-adbm can be used alone or in combination with non-biologic DMARDs.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2448

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 18 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2867
end exclusive: true
exact text: the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-adbm can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-adbm is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease Adalimumab-adbm is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis A
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2326

current approval status

not_reconciled

duplicate text group

dup-aa6337cae2651dae20b3

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-af9c279b490619c8cce0

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 2581
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2569

qualifier mentions

context exact
imumab-adbm is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
kind
age
polarity
not_inferred
span
end
2631
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2617

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2667
end exclusive: true
exact text: 1.4 Ankylosing Spondylitis Adalimumab-adbm is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2526

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 19 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3042
end exclusive: true
exact text: be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-adbm is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease Adalimumab-adbm is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-adbm is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab product
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2468

current approval status

not_reconciled

duplicate text group

dup-646beed26198a72c77f6

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-2b38ae016d4d03a667c4

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 2716
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2704

qualifier mentions

context exact
eatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2793
end exclusive
true
exact text
adults
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2787
context exact
moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2816
end exclusive
true
exact text
pediatric patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2798
context exact
ely active Crohn's disease in adults and pediatric patients 6 years of age and older.
kind
age
polarity
not_inferred
span
end
2831
end exclusive
true
exact text
6 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2817

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2842
end exclusive: true
exact text: 1.5 Crohn's Disease Adalimumab-adbm is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2668

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 20 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3183
end exclusive: true
exact text: ankylosing spondylitis. 1.5 Crohn's Disease Adalimumab-adbm is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-adbm is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ]. 1.7 Plaqu
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2643

current approval status

not_reconciled

duplicate text group

dup-f5770703aa1da6dfa0a3

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-c62d64ae5d07b6d9d3d4

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 2894
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2882

qualifier mentions

context exact
ment of moderately to severely active ulcerative colitis in adult patients.
kind
age
polarity
not_inferred
span
end
2982
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
2968

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2983
end exclusive: true
exact text: 1.6 Ulcerative Colitis Adalimumab-adbm is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2843

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 21 · limitation of use

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 3373
end exclusive: true
exact text: in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-adbm is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ]. 1.7 Plaque Psoriasis Adalimumab-adbm is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and whe
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2784

current approval status

not_reconciled

duplicate text group

dup-8b6548983c7f4bb98f63

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-a128eb3b4b60f6785f11

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 3173
end exclusive: true
exact text: Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ].
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2984

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 22 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3631
end exclusive: true
exact text: patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7) ]. 1.7 Plaque Psoriasis Adalimumab-adbm is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-adbm should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppura
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 2974

current approval status

not_reconciled

duplicate text group

dup-f1e2795752e076f4ba48

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-025cc74fe6b616a810ff

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 3223
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3211

qualifier mentions

context exact
Psoriasis Adalimumab-adbm is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
kind
age
polarity
not_inferred
span
end
3259
end exclusive
true
exact text
adult patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
3245

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 3431
end exclusive: true
exact text: 1.7 Plaque Psoriasis Adalimumab-adbm is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3174

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 23 · risk or warning

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 3806
end exclusive: true
exact text: treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-adbm should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-adbm is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-adbm is indica
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3232

current approval status

not_reconciled

duplicate text group

dup-55bf5a40f351246b2315

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-e081bb34660432b2be7a

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 3606
end exclusive: true
exact text: Adalimumab-adbm should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] .
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3432

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 24 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3944
end exclusive: true
exact text: ically less appropriate. Adalimumab-adbm should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-adbm is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-adbm is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3407

current approval status

not_reconciled

duplicate text group

dup-96fcc0a5ba0d1360dd7f

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-3167af6d13095ae4c342

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 3664
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3652

qualifier mentions

context exact
of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
kind
age
polarity
not_inferred
span
end
3757
end exclusive
true
exact text
12 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
3742

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 3768
end exclusive: true
exact text: 1.8 Hidradenitis Suppurativa Adalimumab-adbm is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3607

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 25 · positive indication candidate

application numbers

BLA761058

brand names

Adalimumab-adbm

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3944
end exclusive: true
exact text: [see Warnings and Precautions (5) ] . 1.8 Hidradenitis Suppurativa Adalimumab-adbm is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-adbm is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3569

current approval status

not_reconciled

duplicate text group

dup-d7a63c1548c690d5ead3

extraction review status

automated_candidate_pending_source_review

generic names

ADALIMUMAB-ADBM

ind-span-c920f74e8f6893c27962

label id

64b7451d-b06d-486b-9b34-a55001711063

positive predicate support span

end: 3809
end exclusive: true
exact text: is indicated
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3797

qualifier mentions

context exact
f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
3895
end exclusive
true
exact text
adults
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
3889
context exact
tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
3918
end exclusive
true
exact text
pediatric patients
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
3900
context exact
posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
3933
end exclusive
true
exact text
2 years of age
label id
64b7451d-b06d-486b-9b34-a55001711063
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start
3919

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 3944
end exclusive: true
exact text: 1.9 Uveitis Adalimumab-adbm is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
label id: 64b7451d-b06d-486b-9b34-a55001711063
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 73b9db47087c15e56d57a98333f3a77a3a8d2e42f1242eb619c5e1ff7ebc2951
start: 3769

source url

https://api.fda.gov/drug/label.json?search=id%3A%2264b7451d-b06d-486b-9b34-a55001711063%22

spl effective date

2024-11-12

spl set id

f9986706-9c75-4335-a54f-09d7716dbcef

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice